The mission of iNFixion Bioscience is to develop drug therapies to treat and prevent the progression of all symptoms associated with Neurofibromatosis Type 1 (NF1), a rare genetic disorder impacting approximately 2.5M people worldwide.
iNFixion’s unique approach to NF1 is to correct a key underlying genetic ‘mechanism of action’, namely the lack of functional Neurofibromin protein, by enhancing the affected person’s natural ability to both produce and maintain healthy Neurofibromin protein. By correcting this root cause mechanism, we believe that a fundamental and preventive impact on disease symptoms, and disease progression, will be achieved.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 3210 Merryfield Row, San Diego,california 92121,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- infixiobio.com
- Keywords
- Neurofibromatosis, Drug Discovery, Orphan Disease, Transcriptional Regulation, Protein Degradation.
- HQ
- San Diego, California
Infixion Bioscience, Inc. Questions
Infixion Bioscience, Inc.'s website is infixiobio.com
Infixion Bioscience, Inc.'s LinkedIn profile is https://www.linkedin.com/company/infixion-bioscience-inc
Infixion Bioscience, Inc. has
8 employees.
View email and phone details for 8
employees at Infixion Bioscience, Inc..
Infixion Bioscience, Inc.'s industry is
Pharmaceutical Manufacturing
Infixion Bioscience, Inc.'s top competitors are
Resolute Science,
Kura Oncology, Inc.,
Society Of Biomolecular Imaging And Informatics,
Launchbio Inc.,
Genomenon, Inc,
Excellos,
Xosomix,
Capricor Therapeutics, Inc.,
Abterra Biosciences,
Palm Therapeutics.
Infixion Bioscience, Inc.'s categories are Pharmaceutical Manufacturing
Infixion Bioscience, Inc.'s founding year is 2017
